Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Kawasaki disease (KD) is an acute, self-limited vasculitis, mainly affecting children younger than 5 years old, with accompanying fever and signs of mucocutaneous inflammation. Intravenous immunoglobulin (IVIG) is the standard treatment for KD; however, ~15% of patients are resistant to IVIG treatment. To identify protein coding genetic variants influencing IVIG resistance, we re-analyzed our previous genome-wide association study (GWAS) data from 296 patients with KD, including 101 IVIG non-responders and 195 IVIG responders. Five nonsynonymous SNPs (nsSNPs) in five immune-related genes, including a previously reported SAMD9L nsSNP (rs10488532; p.Val266Ile), were associated with IVIG non-response (odds ratio [OR] = 1.89-3.46, P = 0.0109-0.0035). In a replication study of the four newly-identified nsSNPs, only one in the interleukin 16 (IL16) gene (rs11556218, p.Asn1147Lys) showed a trend of association with IVIG non-response (OR = 1.54, P = 0.0078). The same IL16 nsSNP was more significantly associated with IVIG non-response in combined analysis of all data (OR = 1.64, P = 1.25 × 10). Furthermore, risk allele combination of the IL16 CT and SAMD9L TT nsSNP genotypes exhibited a very strong effect size (OR = 9.19, P = 3.63 × 10). These results implicate IL16 as involved in the mechanism of IVIG resistance in KD.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s10038-020-0721-2DOI Listing

Publication Analysis

Top Keywords

ivig non-response
12
ivig
9
intravenous immunoglobulin
8
kawasaki disease
8
ivig resistance
8
samd9l nssnp
8
associated ivig
8
association il16
4
il16 asn1147lys
4
asn1147lys polymorphism
4

Similar Publications

[Rare cause of pure white cell aplasia (PWCA) in a 76-year-old male patient].

Inn Med (Heidelb)

September 2025

Klinik für Innere Medizin - Hämatologie/Onkologie und Palliativmedizin, Ev. Stift St. Martin, Koblenz, Deutschland.

Pure white cell aplasia (PWCA) is a rare hematological condition characterized by the complete absence of granulocytes and myeloid precursor cells in the bone marrow. In this case report, we describe a 76-year-old patient with chronic lymphocytic leukemia (CLL) and cutaneous squamous cell carcinoma of the right upper eyelid who developed PWCA after treatment with the immune checkpoint inhibitor (ICI) cemiplimab. The PWCA is a rare side effect of checkpoint inhibitors.

View Article and Find Full Text PDF

Background: The CRP-albumin-lymphocyte (CALLY) index has been demonstrated to be a predictive tool for tumors. However, studies on its role and clinical significance in predicting intravenous immunoglobulin (IVIG) non-response in patients with Kawasaki disease (KD) remains limited.

Methods: A cohort of 975 patients with KD was recruited from four medical centers to examine their clinical and laboratory characteristics.

View Article and Find Full Text PDF

Emergent therapies (ET), which include intravenous immunoglobulin (IVIG), corticosteroids and intravenous anti-Rho(D) immunoglobulin, are used to treat acute episodes of bleeding in children with immune thrombocytopenia (ITP). There are currently no known biomarkers or clinical features predictive of treatment response to any specific ET. Thus, the treatment of ITP remains largely trial and error, exposing patients to potentially ineffective medications, which are often expensive and associated with adverse effects.

View Article and Find Full Text PDF

Objectives: IVIG plus corticosteroids is recommended as the initial intensified therapy for high-risk IVIG-resistant Kawasaki disease (KD) patients. However, some patients still require additional rescue therapy despite this treatment. This study aimed to identify risk factors associated with non-response to initial IVIG plus methylprednisolone therapy in high-risk refractory KD patients.

View Article and Find Full Text PDF

Objectives: In recent years, the use of steroids as an initial adjunctive therapy for patients with Kawasaki disease (KD) at high risk of being unresponsive to intravenous immunoglobulin (IVIG) has shown promising outcomes. However, the optimal duration and tapering method of steroid therapy have not been thoroughly investigated. While the Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy study, which followed the most prominent protocol in Japan, tapers and discontinues steroids for >15 days, our institution reduces and discontinues steroids over six days once inflammation is adequately controlled.

View Article and Find Full Text PDF